GlassScriptPhysician profile
Foley Davis Graham
NPI 1417430893
$4,845.25
in general payments reported to CMS, 2019-2025
25 companies · $718 in 2025
The $718 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,128 · 2022: $1,147 · 2023: $862 · 2024: $990 · 2025: $718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,570.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,569.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,984.98 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $423.04 | 2021-2025 | Ofev, Jardiance, Synjardy |
| Sanofi-Aventis U.S. LLC | $415.72 | 2021-2023 | |
| Amgen INC. | $326.34 | 2022-2025 | Evenity, Prolia |
| Novo Nordisk INC | $292.32 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $209.74 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Mylan Specialty L.P. | $195.00 | 2021-2024 | Yupelri |
| Abbvie INC. | $187.06 | 2021-2024 | |
| Pfizer INC. | $158.28 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $126.83 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $84.41 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $67.81 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $66.30 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $47.17 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.84 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $34.27 | 2021-2025 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $32.82 | 2023 | Quviviq |
| Daiichi Sankyo INC. | $28.41 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $24.61 | 2024 | Zoryve |
| Phathom Pharmaceuticals, INC. | $21.02 | 2024 | Voquezna |
| Insulet Corporation | $20.86 | 2021 | |
| Abbott Laboratories | $17.02 | 2023 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $15.99 | 2021 | |
| Seqirus USA INC | $15.16 | 2025 | Fluad, Flucelvax |
| Pacira Therapeutics, INC. | $13.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Foley Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.